Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corp (NY: CVM )

0.7599 -0.0401 (-5.01%)
Official Closing Price Updated: 8:00 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cel-Sci Corp

< Previous 1 2 3 Next >
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
From CEL-SCI Corporation
Via Business Wire
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering
Via Investor Brand Network
Exposures Product Safety
CEL-SCI Announces Closing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Appoints Robert Watson as Chairperson of the Board
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
From CEL-SCI Corporation
Via Business Wire
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
Via Investor Brand Network
Exposures Product Safety
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
From CEL-SCI Corporation
Via Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.